Candida antigen safe and effective treatment for common warts

Share this content:
Complete clearance of the lesions occurred in 61.1% of the studied patients, and IFN-γ was statistically higher among cases that responded.
Complete clearance of the lesions occurred in 61.1% of the studied patients, and IFN-γ was statistically higher among cases that responded.

(HealthDay News) — Candida antigen is a promising, effective, and safe immunotherapeutic treatment for common warts, according to a study published in the International Journal of Dermatology.

Ahmad Nofal, MD, from Zagazig University in Egypt, and colleagues evaluated the efficacy and safety of Candida antigen for the treatment of common warts and the significance of interferon gamma (IFN-γ) in the prediction of successful therapy. Blood samples were collected from 54 patients with multiple common warts before therapy, cultured, and treated with Candida antigen for evaluation of IFN-γ. Direct injections of Candida antigen were made into the largest wart at 2-week intervals until complete clearance or for a maximum of 5 treatments.

The researchers found that complete clearance of the lesions was seen in 61.1% of the studied patients. Among cases that responded, IFN-γ was statistically higher, compared to that seen in non-responders. No significant adverse effects or recurrence of warts was observed.

"Candida antigen is a promising, effective, and safe immunotherapeutic modality for common warts, and IFN-γ may serve as a good predictor of its therapeutic response," the authors write.

Reference

Nofal A, Marei A, Amer Amin, Amen H. Significance of interferon gamma in the prediction of successful therapy of common warts by intralesional injection of Candida antigen. Int J Dermatol. 2017 Aug 8. doi:10.1111/ild.13709

You must be a registered member of Clinical Advisor to post a comment.

Sign Up for Free e-newsletters